Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
Am J Emerg Med ; 30(1): 264.e3-5, 2012 Jan.
Article in English | MEDLINE | ID: mdl-21277135

ABSTRACT

Superior vena cava (SVC) obstruction leads to a constellation of symptoms and signs that encompass the SVC syndrome. Today, malignancy accounts for 65% of all cases. The most common neoplastic causes are non­small cell lung cancer (50%), small cell lung cancer (25%), lymphoma, and metastasis. Primary cardiac tumors are an extremely rare cause of SVC obstruction. We describe the case of a 48-year-old man who presented with dyspnea, confusion, and facial swelling with cyanosis. The patient developed life-threatening airway obstruction after administration of anxiolytic. The diagnosis of SVC obstruction secondary to a primary cardiac sarcoma was established based on clinical, radiologic, and post-mortem findings. This is one of very few reported cases of a primary cardiac sarcoma causing SVC obstruction.


Subject(s)
Heart Neoplasms/complications , Sarcoma/complications , Superior Vena Cava Syndrome/etiology , Fatal Outcome , Heart Neoplasms/diagnostic imaging , Heart Neoplasms/pathology , Humans , Male , Middle Aged , Myocardium/pathology , Sarcoma/diagnostic imaging , Sarcoma/pathology , Superior Vena Cava Syndrome/diagnosis , Superior Vena Cava Syndrome/diagnostic imaging , Tomography, X-Ray Computed
2.
J Clin Anesth ; 21(1): 44-9, 2009 Feb.
Article in English | MEDLINE | ID: mdl-19232940

ABSTRACT

STUDY OBJECTIVE: To determine whether adding ephedrine to propofol is as effective as adding lidocaine at reducing injection pain, and its effects on hemodynamics. DESIGN: Randomized, double-blinded, controlled trial. SETTING: District general hospital in the United Kingdom. PATIENTS: 156 adult, ASA physical status I, II, and III patients undergoing elective or emergency general anesthesia. INTERVENTIONS: Patients were randomized to one of three groups to receive one mL of 1% lidocaine per 20 mL of 1% propofol (Group L), 15 mg of ephedrine per 20 mL of propofol (Group E15), or 30 mg of ephedrine per 20 mL of propofol (Group E30). MEASUREMENTS AND MAIN RESULTS: Pain on injection, heart rate, and blood pressure at one-minute intervals for ten minutes were recorded. There was no significant difference in injection pain among groups. Group E30 had the least amount of hemodynamic change. CONCLUSION: Adding 30 mg of ephedrine to 20 mL of 1% propofol is as effective as adding lidocaine in preventing injection pain, and it results in a more stable hemodynamic profile.


Subject(s)
Anesthetics, Intravenous/adverse effects , Ephedrine/therapeutic use , Propofol/adverse effects , Vasoconstrictor Agents/therapeutic use , Adolescent , Adult , Aged , Aged, 80 and over , Anesthetics, Intravenous/therapeutic use , Anesthetics, Local/adverse effects , Anesthetics, Local/therapeutic use , Blood Pressure/drug effects , Double-Blind Method , Ephedrine/adverse effects , Female , Heart Rate/drug effects , Hemodynamics/drug effects , Hospitals, General , Humans , Lidocaine/adverse effects , Lidocaine/therapeutic use , Male , Middle Aged , Pain/chemically induced , Pain/prevention & control , Propofol/therapeutic use , Vasoconstrictor Agents/adverse effects , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL